# A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies

> **NCT05629689** · PHASE1 · RECRUITING · sponsor: **GE Healthcare** · enrollment: 50 (estimated)

## Conditions studied

- Malignant Solid Tumor
- Oncology

## Interventions

- **DRUG:** GEH200520 Injection / GEH200521 (18F) Injection - Part A
- **DIAGNOSTIC_TEST:** Dynamic and Static - PET/CT scan
- **DRUG:** GEH200520 Injection / GEH200521 (18F) Injection - Part B
- **DIAGNOSTIC_TEST:** Static - PET/CT scan

## Key facts

- **NCT ID:** NCT05629689
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-27
- **Primary completion:** 2029-03-10
- **Final completion:** 2029-03-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629689, "A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05629689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*